Joe Sterling

Notable Movers: Seagate Technology PLC (NASDAQ:STX), Cognizant Technology Solutions Corp (NASDAQ:CTSH)

Seagate Technology PLC (NASDAQ:STX) shares went down -0.99% or -0.29 points to reach at $28.90 during the course of session. The stock traded in the range of $28.30 – $29.43 during its most recent trading session. The stock has total market worth of $8.44B and it has total of 298.48M outstanding shares. Relative strength index (RSI-14) for Seagate Technology PLC (NASDAQ:STX) is at 71.03.

Historically the stock has climbed 20.37% in the past week and soared 27.20% in the last four weeks, the stock illustrate that its three months performance stands at 16.61% while its year to date performance is at -16.98%. Stock’s price oscillated from $52.88 to $18.42 during past twelve months. The stock is now trading at a distance of 18.61% from SMA-20. The stock is presently trading 28.16% above from its SMA-50. In the current trading session, the stock’s price moved -4.15% below from its SMA-200. If we take a look on its volatility, 4.31 percent was seen in a week and for the month it was 4.13 percent. Stock’s beta value stands at 2.41 and its ATR value is at 1.25.

Seagate Technology PLC (NASDAQ:STX) reported on July 12, 2016 that it filed on Friday, April 8, 2016, restated interim financial statements and a revised management’s discussion and analysis for the third-quarter ended September 30, 2015 which can be found on SEDAR (www.sedar.com) under the Company’s profile. This followed the filing on Friday, March 18, 2016 of restated audited financial statements and a revised MD&A for the Company for the year ended December 31, 2014 and the filings on Thursday, March 24, 2016 and Friday, April 1, 2016 of restated interim financial statements and revised MD&As for the first and second quarters ended March 31, 2015 and June 30, 2015, respectively.

As previously announced (see press releases dated December 31, 2015 and January 12, 2016), the Ontario Securities Commission (the “OSC”) issued a management cease trade order (“MCTO”) prohibiting the Company’s Chief Executive Officer and Chief Financial Officer from trading, directly or indirectly, in the securities of Starrex until two full business days following the receipt by the OSC of all filings that the Company is required to make under Ontario securities law or other order of the Director of the OSC. The MCTO did not affect the ability of persons who are not insiders of Starrex to trade its securities.

Starrex is currently in discussions with staff of the OSC regarding any comments which such staff may have regarding the refilings made to date. Starrex intends to issue further bi-weekly status reports pending confirmation or other response from staff of the OSC regarding the refilings made to date or other conclusion to this process.

Cognizant Technology Solutions Corp (NASDAQ:CTSH) shares slipped -2.00% or -1.18 points in order to take the company’s stock at the price of $57.76. Stock’s price oscillated between $58.07 and $56.52 for intra-day trading. Relative strength index (RSI-14) for Cognizant Technology Solutions Corp (NASDAQ:CTSH) is at 44.33. It has total market capitalization of $35.26B.

Historically the stock has slipped -0.29% in the past week and plunged -3.14% in the last four weeks, the stock illustrate that its three months performance stands at -3.85% while its year to date performance is at -3.77%. The stock hit the peak level of one year at $69.80 and touched the minimum level of $51.22. Shares are trading -17.25% off from the 52-week high and +12.77% above from the 52-week bottom level. The stock is now trading at a distance of -1.25% from SMA-20. The stock is presently trading -3.81% below from its SMA-50. In the current trading session, the stock’s price moved -5.17% below from its SMA-200. The company has a Return on Assets of 13.50%. The company currently has a Return on Equity of 18.60% and a Return on Investment of 15.20%.

Cognizant Technology Solutions Corp (NASDAQ:CTSH) a leading provider of information technology, consulting, and business process outsourcing services, on July 14, 2016 reported it will announce results for the second quarter of 2016 on Friday, August 5, 2016, before market open.

Cognizant is a leading provider of information technology, consulting, and business process services, dedicated to helping the world’s leading companies build stronger businesses. Headquartered in Teaneck, New Jersey (U.S.), Cognizant combines a passion for client satisfaction, technology innovation, deep industry and business process expertise, and a global, collaborative workforce that embodies the future of work. With over 100 development and delivery centers worldwide and approximately 233,000 employees as of March 31, 2016, Cognizant is a member of the NASDAQ-100, the S&P 500, the Forbes Global 2000, and the Fortune 500 and is ranked among the top performing and fastest growing companies in the world.

Technology Stocks to Track: QUALCOMM, Inc. (NASDAQ:QCOM), MGT Capital Investments Inc. (NYSEMKT:MGT)

QUALCOMM, Inc. (NASDAQ:QCOM) shares went down -0.24% or -0.13 points to reach at $54.75 during the course of session. The stock traded in the range of $54.17 – $54.86 during its most recent trading session. The stock has total market worth of $80.50B and it has total of 1.47B outstanding shares. Relative strength index (RSI-14) for QUALCOMM, Inc. (NASDAQ:QCOM) is at 58.87.

Historically the stock has climbed 1.03% in the past week and soared 2.76% in the last four weeks, the stock illustrate that its three months performance stands at 8.26% while its year to date performance is at 11.61%. Stock’s price oscillated from $66.05 to $42.24 during past twelve months. The stock is now trading at a distance of 2.33% from SMA-20. The stock is presently trading 2.72% above from its SMA-50. In the current trading session, the stock’s price moved 7.39% above from its SMA-200. If we take a look on its volatility, 1.17 percent was seen in a week and for the month it was 1.78 percent. Stock’s beta value stands at 1.17 and its ATR value is at 1.01.

QUALCOMM, Inc. (NASDAQ:QCOM) on July 13, 2016 announced that it has revised its third quarter fiscal 2016 earnings conference call time on Wednesday, July 20, 2016. The call will now begin at 1:30 p.m. Pacific Time (PT), 15 minutes earlier than previously scheduled in order to avoid overlap with the earnings calls of other companies in the sector. The Company’s financial results for the quarter will be released on the same day after the close of the market on the Company’s Investor Relations website, at http://investor.qualcomm.com/results.cfm. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov.

Qualcomm Incorporated (QCOM) is a world leader in 3G, 4G and next-generation wireless technologies. Qualcomm Incorporated includes Qualcomm’s licensing business, QTL, and the vast majority of its patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of Qualcomm’s engineering, research and development functions, and substantially all of its products and services businesses, including its semiconductor business, QCT.

MGT Capital Investments Inc. (NYSEMKT:MGT) shares rose 10.91% or +0.36 points in order to take the company’s stock at the price of $3.66. Stock’s price oscillated between $3.94 and $3.47 for intra-day trading. Relative strength index (RSI-14) for MGT Capital Investments Inc. (NYSEMKT:MGT) is at 50.21. It has total market capitalization of $90.57M.

Historically the stock has slipped -14.69% in the past week and soared 14.73% in the last four weeks, the stock illustrate that its three months performance stands at 1364.00% while its year to date performance is at 1491.30%. The stock hit the peak level of one year at $5.58 and touched the minimum level of $0.15. Shares are trading -34.41% off from the 52-week high and +2338.37% above from the 52-week bottom level. The stock is now trading at a distance of 1.16% from SMA-20. The stock is presently trading 32.59% above from its SMA-50. In the current trading session, the stock’s price moved 310.40% above from its SMA-200.

MGT Capital Investments Inc. (NYSEMKT:MGT) on July 15, 2016 announced Sentinel MGT, an intrusion monitoring system, a cybersecurity product designed to protect corporate and enterprise intranets from sophisticated hacking threats. MGT also announced plans for a consumer product based on the technology, due to be released in November. The underlying technology was purchased from Cyberdonix, Inc. for 150,000 restricted shares of MGT stock.

In an article published yesterday, Inc. Magazine correctly outlined the five most important classes of cybersecurity technologies needed to address the latest threats facing organizations and consumers. These are protecting the rapidly expanding Internet of Things (IOT), protecting the cloud, moving to a proactive defense, protecting individual privacy and securing mobile computing platforms.

Sentinel MGT joins the other technologies acquired by MGT — D-Vasive, Demonsaw and E-Tagged — to make MGT the only company developing targeted solutions for all of these threats to both the consumer and enterprise markets. These technologies, taken together, comprise the world’s first comprehensive Anti-Hacking system.

Sentinel MGT features a new approach towards monitoring network traffic that outpaces every other approach in the industry. The system, composed of a passive hardware device connected to an enterprise Ethernet, monitors network traffic for suspicious activity using sophisticated algorithms, providing an early warning system that alerts the owner before irreparable damage can be done. The device requires no setup or user configuration. The user merely plugs it into an intranet and it communicates anomalous packets to an MGT server, where they are analyzed and appropriate alerts are instantaneously transmitted to the enterprise IT department.

Sentinel MGT mitigates risk by greatly reducing the time a hacker has to operate inside protected networks, planting malware and stealing data. It also allows for an investigation to begin while the attack is in progress, rather than after the perpetrator has left the system. This Anti-Hacking system allows organizations, for the first time, to take a proactive rather than a reactive approach to cybersecurity.

Healthcare Stock’s Buzz: Mallinckrodt PLC (NYSE:MNK), Anthem Inc (NYSE:ANTM)

Mallinckrodt PLC (NYSE:MNK) shares went up 0.02% or +0.01 points to reach at $62.45 during the course of session. The stock has total market worth of $6.83 and it has total of 109.33 outstanding shares. Relative strength index (RSI-14) for Mallinckrodt PLC (NYSE:MNK) is at 56.54.

Historically the stock has climbed 0.26% in the past week and soared 3.88% in the last four weeks, the stock illustrate that its three months performance stands at 5.65% while its year to date performance is at -16.32%. Stock’s price oscillated from $127.00 to $50.90 during past twelve months. The stock is now trading at a distance of 4.59% from SMA-20. The stock is presently trading 3.24% above from its SMA-50. In the current trading session, the stock’s price moved -2.45% below from its SMA-200. If we take a look on its volatility, 1.96 percent was seen in a week and for the month it was 3.58 percent. Stock’s ATR value is at 2.03.

Mallinckrodt PLC (NYSE:MNK) on July 5, 2016 announced new retrospective health economic data on H.P. Acthar Gel (RCI), which may be an option for the management of multiple sclerosis (MS) relapses. The manuscript, recently published in Advances in Therapy compares the health care resource use and costs of patients treated with Acthar to those treated with plasmapheresis (PMP) or intravenous immunoglobulin (IVIG). Researchers at the University of Washington conducted the analysis, which was supported by a grant from Mallinckrodt Pharmaceuticals.

The cohort analysis titled, “Health Care Costs and Resource Utilization in Multiple Sclerosis Relapse Patients,”aimed to describe and generate hypotheses related to health care utilization, outcomes and costs among patients with MS who experienced multiple relapses. Researchers reviewed 12- and 24-month health care utilization and costs among patients who received Acthar (n=213 and n=96, respectively) compared to patients who were treated with PMP/IVIG (n=226 and n=132, respectively), in a commercially insured U.S. population. Claims data from the Truven Health Analytics MarketScan Commercial Claims and Encounters Databases were examined between July 1, 2007, to Dec. 31, 2012, for the 12-month analyses or through Dec. 31, 2011, for the 24-month analyses. Patients in both the 12- and 24-month analyses were followed for outcomes until Dec. 31, 2013.

Findings from this retrospective, observational study among MS patients include:

  • 12-month outcomes: Compared to PMP/IVIG, Acthar had lower hospitalizations (0.2 vs. 0.6, p=0.0002), outpatient services (31 vs. 48, p<0.0001), inpatient ($15,300 lower, p=0.001) and outpatient costs ($54,100 lower, p<0.0001) with similar total costs ($5,000 higher, p=0.69).
  • 24-month outcomes: Compared to PMP/IVIG, Acthar had lower hospitalizations (0.5 vs. 1.0, p=0.04), outpatient services (56 vs. 87, p<0.0001), inpatient ($17,400 lower, p=0.03) and outpatient costs ($121,000 lower, p<0.0001) with similar total costs ($33,400 lower, p=0.13).
  • The costs of medications were increased in the group that received Acthar prescriptions, these costs were offset by 93% (among the cohort with 12 months of follow-up) and 132% (among the cohort with 24 months of follow-up) by the relative decrease in inpatient and outpatient costs among the group that received Acthar prescriptions.

Anthem Inc (NYSE:ANTM) shares rose 0.31% or +0.42 points in order to take the company’s stock at the price of $134.31. Relative strength index (RSI-14) for Anthem Inc (NYSE:ANTM) is at 57.10. It has total market capitalization of $35.42B.

Historically the stock has climbed 1.63% in the past week and soared 2.83% in the last four weeks, the stock illustrate that its three months performance stands at -5.56% while its year to date performance is at -2.73%. The stock hit the peak level of one year at $158.84 and touched the minimum level of $115.63. Shares are trading -14.49% off from the 52-week high and +17.30% above from the 52-week bottom level. The stock is now trading at a distance of 2.66% from SMA-20. The stock is presently trading 1.50% above from its SMA-50. In the current trading session, the stock’s price moved -0.41% below from its SMA-200. The company has a Return on Assets of 3.80%. The company currently has a Return on Equity of 10.30% and a Return on Investment of 8.30%.

Anthem Inc (NYSE:ANTM) on July 11, 2016 reported it will release second quarter 2016 financial results on July 27, 2016, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning.

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small employer, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association.

Healthcare Stocks on the Move: Agilent Technologies Inc (NYSE:A), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Agilent Technologies Inc (NYSE:A) shares went down -0.28% or -0.13 points to reach at $46.67 during the course of session. The stock has total market worth of $15.15B and it has total of 325.00M outstanding shares. Relative strength index (RSI-14) for Agilent Technologies Inc (NYSE:A) is at 61.38.

Historically the stock has climbed 2.62% in the past week and soared 4.12% in the last four weeks, the stock illustrate that its three months performance stands at 14.38% while its year to date performance is at 12.24%. Stock’s price oscillated from $46.98 to $33.12 during past twelve months. The stock is now trading at a distance of 3.54% from SMA-20. The stock is presently trading 4.56% above from its SMA-50. In the current trading session, the stock’s price moved 16.56% above from its SMA-200. If we take a look on its volatility, 1.14 percent was seen in a week and for the month it was 1.64 percent. Stock’s beta value stands at 1.45 and its ATR value is at 0.78.

Agilent Technologies Inc (NYSE:A) on July 11, 2016 announced it will be hosting its 2016 Science and Technology Symposium series in South East Asia. The series is set to bring scientific communities and Agilent experts together in a unique opportunity to discuss the latest solutions to the scientific and business challenges laboratories face on July 11, 2016.

Taking place in three countries, the Symposium will focus on food and environmental testing and lab productivity — key issues faced by Agilent customers in the region. For the first time, scientists and researchers will get a one-stop opportunity to explore complete Agilent solutions to all aspects of laboratory challenges — from specific techniques in sample preparation, measurement and analysis to strategies for laboratory cost and efficiency improvement. Other topics to be covered: regulatory requirements and consumer trends in data privacy and staff training.

Key presentations include:

  • Case studies on laboratory technology life cycle management, with insights into ensuring laboratory operation continuity.
  • A demonstration — through a nutrient extraction of soil application — of how the new Agilent 5110 ICP-OES with Advanced Valve System can shorten analysis time without compromising analytical performance, thus enhancing laboratory profitability by minimizing instrument running costs.
  • A talk on how to achieve cost, time and solvent savings in the monitoring of 16 parent polycyclic aromatic hydrocarbons (PAHs) in the environment using Online Solid Phase Extraction and UHPLC.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares rose 7.33% or +3.63 points in order to take the company’s stock at the price of $53.17. Relative strength index (RSI-14) for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is at 48.91. It has total market capitalization of $2.23B.

Historically the stock has slipped -0.34% in the past week and plunged -15.12% in the last four weeks, the stock illustrate that its three months performance stands at -24.95% while its year to date performance is at -52.60%. The stock hit the peak level of one year at $137.05 and touched the minimum level of $46.52. Shares are trading -61.20% off from the 52-week high and +14.29% above from the 52-week bottom level. The stock is now trading at a distance of 3.06% from SMA-20. The stock is presently trading -10.85% below from its SMA-50. In the current trading session, the stock’s price moved -29.80% below from its SMA-200. The company has a Return on Assets of -34.90%. The company currently has a Return on Equity of -36.90%.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 14, 2016 announced positive topline data from the pivotal Phase 3 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of Mucopolysaccharidosis 7 (MPS 7, Sly syndrome). The study met its primary endpoint of reducing urinary GAG (dermatan sulfate) excretion after 24 weeks of treatment, demonstrating a reduction from baseline of 64.8 percent (p<0.0001). The data are being presented at the 14th International Symposium on MPS and Related Diseases.

“Treatment with rhGUS showed a rapid and sustained reduction in urinary GAG excretion, as well as signs of clinical improvement in this heterogeneous patient population,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.  “We look forward to working with the FDA and EMA to file these data with the goal of bringing this potential treatment to patients with MPS7 who currently have no other options.”

For the 6MWT, the improvement (±SE) was 20.8 (±16.75) meters at 24 weeks of treatment based on the estimates from 9 patients who had any change from baseline data. Three of these patients demonstrated an improvement of a magnitude equal or greater than the MID with increases of 65 meters, 80 meters and 83 meters at 24 weeks compared to baseline. For the fatigue scores, four patients improved at or above the MID level after 24 weeks of treatment and nine of 12 showed improvement at some point during the study.

All patients experienced treatment emergent adverse events, which were generally mild to moderate in severity. Six of the eight patients with infusion associated reactions (IARs) on rhGUS treatment had events involving the IV catheter. There were two patients that each had a single hypersensitivity-type IAR, including one Grade 3 treatment-related anaphylactoid serious adverse event (SAE) that resulted from an infusion rate error. The second patient had mild fever and diaphoresis that resolved without treatment. No patients demonstrated recurring hypersensitivity reactions to infusions. There was a second SAE that was a Grade 2 unrelated event from an accidental injury. There were no deaths and no treatment discontinuations or missed infusions due to AEs. Seven of the 12 patients developed anti-rhGUS antibodies, which were not associated with immune-mediated AEs.

Investor’s Alert: Quintiles Transnational Holdings Inc (NYSE:Q), CIGNA Corporation (NYSE:CI)

Quintiles Transnational Holdings Inc (NYSE:Q) shares went down -0.08% or -0.06 points to reach at $71.67 during the course of session. The stock traded in the range of $80.45 – $55.01 during its most recent trading session. The stock has total market worth of $8.44B and it has total of 119.67M outstanding shares. Relative strength index (RSI-14) for Quintiles Transnational Holdings Inc (NYSE:Q) is at 67.48.

Historically the stock has climbed 0.36% in the past week and soared 10.09% in the last four weeks, the stock illustrate that its three months performance stands at 2.25% while its year to date performance is at 4.38%. Stock’s price oscillated from $80.45 to $55.01 during past twelve months. The stock is now trading at a distance of 7.30% from SMA-20. The stock is presently trading 7.79% above from its SMA-50. In the current trading session, the stock’s price moved 7.84% above from its SMA-200. If we take a look on its volatility, 1.62 percent was seen in a week and for the month it was 1.86 percent. Stock’s ATR value is at 1.26.

Quintiles Transnational Holdings Inc (NYSE:Q) on July 13, 2016 reported it will release its second quarter 2016 financial results Wednesday, July 27, 2016 prior to its quarterly earnings call at 8:00 a.m. EDT.

Quintiles Transnational Holdings Inc., through its subsidiary, Quintiles Transnational Corp., provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. The company’s Product Development segment offers project management and clinical monitoring services, including study design and operational planning, investigator/site recruitment, site and regulatory start up, patient recruitment, clinical monitoring, project management for conducting various multi-site trials, and late phase interventional services; and clinical trial support services comprising clinical data management, biostatistical, cardiac safety and ECG laboratory, safety and pharmacovigilance, and phase I clinical pharmacology services, as well as clinical trial, genomic, and bioanalytical laboratory services. This segment also provides strategic planning and design services for biomarkers, genomics, and personalized medicine, as well as offers model-based drug development and regulatory affairs services; and consulting services, such as product development strategy, regulatory and compliance, and process and IT implementation consulting services.

CIGNA Corporation (NYSE:CI) shares rose 1.18% or +1.53 points in order to take the company’s stock at the price of $131.67. Relative strength index (RSI-14) for CIGNA Corporation (NYSE:CI) is at 57.52. It has total market capitalization of $34.21B.

Historically the stock has climbed 1.60% in the past week and soared 4.04% in the last four weeks, the stock illustrate that its three months performance stands at -3.64% while its year to date performance is at -9.99%. The stock hit the peak level of one year at $158.00 and touched the minimum level of $121.87. Shares are trading -16.64% off from the 52-week high and +8.04% above from the 52-week bottom level. The stock is now trading at a distance of 2.72% from SMA-20. The stock is presently trading 2.22% above from its SMA-50. In the current trading session, the stock’s price moved -2.62% below from its SMA-200. The company has a Return on Assets of 3.60%. The company currently has a Return on Equity of 17.40% and a Return on Investment of 12.10%.

CIGNA Corporation (NYSE:CI) on July 14, 2016 reported it has selected Shelby County Government as the winner of its annual Cigna Well-Being Award in Tennessee for demonstrating a commitment to improving the health and well-being of employees through workplace wellness programs.

Shelby County Government offers employees multiple avenues to improve their health, including free biometric screenings and health assessments, access to personalized health coaching, onsite fitness centers and a bike rental program, and health education programs and seminars.

The County also offers programs to help employees better manage chronic conditions and sponsors activities that help foster a culture of health, including produce giveaways, health fairs, healthy cooking demonstrations, healthy food choices in vending machines and fitness demonstrations and activities.

Participation and engagement rates in the County’s wellness program have increased each year since the program began in 2012. Over 8 in 10 county employees have completed a health assessment or biometric screening, and Mayor Luttrell’s Healthy Shelby 5K is in its fourth year. Employees receive a discounted race entry and are encouraged to create teams among departments. Proceeds from the race directly benefit one of the three Healthy Shelby initiatives: infant mortality, chronic disease, and end of life care. Since 2013, nearly $95,000 has been raised for these initiatives through participation in the race.

Shelby County Government has been recognized as a Healthier Tennessee Workplace through the Governor’s Foundation for Health and Wellness and is also a recipient of the American Heart Association’s Fit Friendly award, and the Memphis Business Group on Health’s Culture of Health award.

According to the Centers for Disease Control and Prevention (CDC), U.S. employers lose more than $225 billion each year in productivity due to employee health problems. Cigna created the Well-Being Award to recognize employer clients that have a positive impact on the health and well-being of their workforce.

Stock on Analysts Radar: Kinross Gold Corporation (USA) (NYSE:KGC)

Kinross Gold Corporation (USA) (NYSE:KGC) plunged -1.67% during previous trade, a total of 9.84M shares exchanged hands compared with its average trading volume of 16.54M shares. The stock has a market capitalization of $6.48B along with 1.24B outstanding shares. On year trading price range hit the peak level of $5.82 and touched the lowest level of $1.31.

Most recently the company’s price target was revised on 07/14/16 and according to 18 analysts stock’s price will reach at $6.16 during 52 weeks with standard deviation of 1.47. Stock’s minimum price target estimates has been figured out at $3.28.00 while the maximum price target forecast is established at $8.00, if we look at the price target with an optimistic approach it has upside potential of 183% from its latest closing price of $5.31.

Historically, if we look at price target revisions during last one month, three weeks ago stock’s price target was revised on 06/02/16 by the analysts. The bullish price estimates of the stock is set at $6.00 while the bearish estimates kept at $2.90 over the next one year. Stock’s 52-week target was retained at $4.41, the estimates indicates a standard deviation of 1.11. After that the stock’s target price was revised on 06/29/16, approximately two weeks ago. Kinross Gold Corporation (USA) (NYSE:KGC) highest price target was set at $7.00 and lowest target was at $2.90. The company’s one year price target was secure at $4.69 and its standard deviation of 1.47. Moreover one week ago on 07/06/16  the company’s price target was revised at $4.81 with 52 week price target range of $7.00 – $2.90. The estimates signifies a standard deviation of 1.39.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 2.50. ABR value is precisely based on brokerage recommendations, where out of 14 brokerage recommendations 3 rate Kinross Gold Corporation (USA) (NYSE:KGC) stock a Strong Buy, 3 rate the stocks of the company a Buy, 7 rate Hold, 0 rate Sell and 1 recommend a Strong Sell. Most recently on 7/14/2016 the stock of Kinross Gold Corporation (USA) (NYSE:KGC) upgraded by Jefferies from Underperform to Hold. However previously on 7/6/2016 it was upgraded by Deutsche Bank from Sell to Hold. A research note issued on 7/1/2016 the stock was upgraded by Macquarie from Underperform to Neutral.

Kinross Gold Corporation (USA) (NYSE:KGC) performance over the past one year advanced 162.87%, during the last six months the stock rose 231.87%. Quarterly performance of the company shows optimistic momentum of 24.94% while its last one month trend is positive with 1.72%. Stock’s weekly performance expressed down trend of -3.98%.

According to consensus agreement of 15 analysts Kinross Gold Corporation (USA) (NYSE:KGC) will report earnings per share of $0.01 in their quarterly report and it is expected to announce the company’s results on 7/27/2016 AMC. For the current quarter the company has high EPS estimates of $0.02 in contradiction of low EPS estimates of $-0.01. However a year ago for the same quarter the company has reported $-0.01 EPS.

Analyst Perspectives on Price Target History: Weatherford International Plc (NYSE:WFT)

Weatherford International Plc (NYSE:WFT) soared 0.67% during previous trade, a total of 17.89M shares exchanged hands compared with its average trading volume of 23.90M shares. The stock has a market capitalization of $5.36B along with 895.69M outstanding shares. On year trading price range hit the peak level of $11.52 and touched the lowest level of $4.71.

Most recently the company’s price target was revised on 07/12/16 and according to 32 analysts stock’s price will reach at $7.86 during 52 weeks with standard deviation of 2.12. Stock’s minimum price target estimates has been figured out at $4.00 while the maximum price target forecast is established at $13.00, if we look at the price target with an optimistic approach it has upside potential of 116% from its latest closing price of $6.02.

Historically, if we look at price target revisions during last one month, three weeks ago stock’s price target was revised on 06/13/16 by the analysts. The bullish price estimates of the stock is set at $13.00 while the bearish estimates kept at $4.00 over the next one year. Stock’s 52-week target was retained at $7.76, the estimates indicates a standard deviation of 2.17. After that the stock’s target price was revised on 06/24/16, approximately two weeks ago. Weatherford International Plc (NYSE:WFT) highest price target was set at $13.00 and lowest target was at $4.00. The company’s one year price target was secure at $7.72 and its standard deviation of 2.12. Moreover one week ago on 06/30/16 the company’s price target was revised at $7.72 with 52 week price target range of $13.00 – $4.00. The estimates signifies a standard deviation of 2.12.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 2.20. ABR value is precisely based on brokerage recommendations, where out of 25 brokerage recommendations 13 rate Weatherford International Plc (NYSE:WFT) stock a Strong Buy, 0 rate the stocks of the company a Buy, 8 rate Hold, 2 rate Sell and 2 recommend a Strong Sell. Most recently on 6/6/2016 the stock of Weatherford International Plc (NYSE:WFT) upgraded by Barclays from Equal Weight to Overweight. However previously on 6/3/2016 it was upgraded by Piper Jaffray from Neutral to Overweight. A research note issued on 5/10/2016 the stock was downgraded by Societe Generale from Buy to Hold.

Weatherford International Plc (NYSE:WFT) performance over the past one year plunged -46.25%, during the last six months the stock slipped -9.47%. Quarterly performance of the company shows declining momentum of -20.89% while its last one month trend is negative with -3.83%. Stock’s weekly performance expressed up trend of 12.31%.

According to consensus agreement of 36 analysts Weatherford International Plc (NYSE:WFT) will report earnings per share of $-0.29 in their quarterly report and it is expected to announce the company’s results on 7/27/2016 AMC. For the current quarter the company has high EPS estimates of $-0.26 in contradiction of low EPS estimates of $-0.35. However a year ago for the same quarter the company has reported $-0.1 EPS.

PG&E Corporation (NYSE:PCG) : Look out for Analyst’s Recommendation

PG&E Corporation (NYSE:PCG) stock exchanged hands 3.03M shares versus average trading capacity of 2.91M shares, while its shares total market worth is $31.88B along with 496.04M outstanding shares. Its shares ended last trading session at the price of $64.62 whereas a number of traders indicating mean target price will hit $64.43 over the next twelve months, mean value of price target most recently revised on 07/13/16. The highest estimates of price target are $54.00 and low forecast is $71.00 based on the opinion of 15 analysts. The price target estimates represents a standard deviation of 4.59. However brokerage recommendations suggests an ABR of 1.50 based on calls of 9 experts, where 6 brokers polls the stock a Strong Buy, 1 suggest the stock a Buy, 2 suggest Hold, 0 are rating the stock as Sell while 0 as Strong Sell.

RBC Capital Mkts issued rating on the stock of PG&E Corporation (NYSE:PCG) in a research note issued to investors on 7/15/2016, the stock received “Upgrade” rating from Sector Perform to Outperform from $60 to $71. Additionally Mizuho issued their Verdict on the stock of the company, on record date of Jun-29-16 the stock was “Reiterated” as Buy from $64 to $67 besides on May-24-16 the stock was “Reiterated” by Mizuho as Buy from $56 to $64. Furthermore on Jan-27-16 the stock was “Upgraded” by Goldman from Neutral to Buy.

The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. Total 12 number of trades held during last 3 months and 47 during last 12 months, out of them 11 numbers of buys held in last 3 months and 29 buys in last 12 months. Whereas 1 numbers of sells held in last 3 months and 18 sells over the past 12 months.

Currently, 0.20% shares of PG&E Corporation (NYSE:PCG) are owned by insiders with -4.87% six-month change in the insider ownership. According to U.S. Security Exchange Commission Filing, Earley Anthony F JR is one of the major insider shareholder of the company’s stock, the insider owns 366,287 shares reported on Mar 1, 2016. Johns Christopher P       is second leading insider shareholder, as of Mar 2, 2015 the insider owns 79,815 shares of the stock. Williams Geisha J is another major insider shareholder of the stock, as per record date of Mar 1, 2016 insider owns 61,612 shares of the stock.

PG&E Corporation (NYSE:PCG) is expected to release the earnings of its current quarter on 7/28/2016 BMO. The company is expected to release $1 EPS during current quarter according to 11 analysts whereas the company reported $0.91 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $0.84 and high estimate of $1.19. PG&E Corporation (NYSE:PCG)’s average revenue estimates for the current quarter are 4.55B according to 6 number of analysts. However its lowest revenue estimates are 4.15B and highest revenue estimates are 5.24B. A year ago the company’s sales were 4.22B. Its yearly sales growth estimates are 8.00%.

Broker’s Roundup on Rating and Recommendations: Harley-Davidson Inc (NYSE:HOG)

Harley-Davidson Inc (NYSE:HOG) stock exchanged hands 2.37M shares versus average trading capacity of 181.09M shares, while its shares total market worth is $8.64B along with 181.09M outstanding shares. Its shares ended last trading session at the price of $48.10 whereas a number of traders indicating mean target price will hit $51.00 over the next twelve months, mean value of price target most recently revised on 07/14/16. The highest estimates of price target are $61.00 and low forecast is $40.00 based on the opinion of 12 analysts. The price target estimates represents a standard deviation of 5.67. However brokerage recommendations suggests an ABR of 2.04 based on calls of 14 experts, where 5 brokers polls the stock a Strong Buy, 3 suggest the stock a Buy, 6 suggest Hold, 0 are rating the stock as Sell while 0 as Strong Sell.

Stifel issued rating on the stock of Harley-Davidson Inc (NYSE:HOG) in a research note issued to investors on 7/15/2016, the stock received “Downgrade” rating from Buy to Hold. Additionally UBS issued their Verdict on the stock of the company, on record date of Jul-06-16 the stock was “Downgraded” from Buy to Neutral at $57 besides on Jul-05-16 the stock was “Downgraded” by Robert W. Baird from Outperform to Neutral at $54. Furthermore on Jun-06-16 the stock was “Downgraded” by Goldman from Buy to Neutral from $55 to $50.

The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. Total 3 number of trades held during last 3 months and 26 during last 12 months, out of them 0 numbers of buys held in last 3 months and 0 buys in last 12 months. Whereas 3 numbers of sells held in last 3 months and 26 sells over the past 12 months.

Currently, 0.10% shares of Harley-Davidson Inc (NYSE:HOG) are owned by insiders with -15.04% six-month change in the insider ownership. According to U.S. Security Exchange Commission Filing, Wandell Keith E is one of the major insider shareholder of the company’s stock, the insider owns 146,860 shares reported on Apr 30, 2015. Levatich Matthew S is second leading insider shareholder, as of Feb 4, 2016 the insider owns 56,898 shares of the stock. Olin John A is another major insider shareholder of the stock, as per record date of Feb 4, 2016 insider owns 32,175 shares of the stock.

Harley-Davidson Inc (NYSE:HOG) is expected to release the earnings of its current quarter on 8/3/2016 BMO. The company is expected to release $1.54 EPS during current quarter according to 17 analysts whereas the company reported $1.44 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $1.48 and high estimate of $1.6. Harley-Davidson Inc (NYSE:HOG)’s average revenue estimates for the current quarter are 1.67B according to 14 number of analysts. However its lowest revenue estimates are 1.64B and highest revenue estimates are 1.71B. A year ago the company’s sales were 1.65B. Its yearly sales growth estimates are 1.20%.

Can Brown & Brown, Inc. (NYSE:BRO) Run Higher on Earnings Estimates?

Brown & Brown, Inc. (NYSE:BRO) plunged -0.17% or -0.06 points during previous trade after opening at the price of $36.25, a total of 1.07M shares exchanged hands compared with its average trading volume of 715,899.00 shares. The stock has a market capitalization of $5.04B and it has 140.02M outstanding shares.

According to consensus agreement of 16 analysts Brown & Brown, Inc. (NYSE:BRO) will report earnings per share of $0.44 in their quarterly report and it is expected to announce the company’s results on 7/18/2016 AMC. For the current quarter the company has highest EPS estimates of $0.46 and low forecast is $0.42. However a year ago for the same quarter the company has reported $0.43 earnings per share.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $0.42 while the company reported $0.44 EPS on 4/18/2016 After Market Close with a difference of 0.02 marking a surprise factor of 4.76%.

Previously for the quarter ended on 12/2015, Brown & Brown, Inc. (NYSE:BRO)’s expected mean EPS was $0.36, the company reported its quarterly earnings per share of $0.41 on 1/25/2016 After Market Close, beating the analysts’ consensus estimate by 0.05 with surprise factor of 13.89%.

Brown & Brown, Inc. (NYSE:BRO)’s mean EPS estimate was $0.47 for the quarter ended on 9/2015, while it reported EPS of $0.47 on 10/19/2015 After Market Close.

Back on 7/20/2015 the company’s estimated EPS value was $0.43 and it reported $0.43 earnings per share (EPS) for the quarter ended on 6/2015.

Brown & Brown, Inc. (NYSE:BRO)’s average EPS forecast for the current year is $1.77 according to 16 analysts making projections. The most expectant earnings per share estimate of the stock is set at $1.8 while the conservative estimates kept at $1.73 over the current year. Having a look at the historical EPS report, the company attained $1.7 EPS for the previous year. While revenue estimates for the current year is 1.75B, setting the highest revenues estimates of 1.77B and indicating lowest revenues at 1.73B according to agreement of 13 number of analysts. Current revenue movements show that, the company has set average revenue estimates of 440.3M covering forecast of 11 analysts. The company indicates a peak revenue level of 447M and 434.79M at bottom level.

Having a glance at growth estimates of the company, it has current quarter growth estimates of 2.30% whereas for next quarter it has 4.30% estimations over growth. Its forecasts over growth are 4.10% during current year while analysts’ growth estimation for the next year is 7.90%. Past 5 years growth of Brown & Brown, Inc. (NYSE:BRO) observed at 10.15%, and for the next five years the analysts that follow this company are expecting its growth at 9.00%.

Brown & Brown, Inc. (NYSE:BRO) reached at $36.04 price level during last trade its distance from 20 days simple moving average is -1.05%, and its distance from 50 days simple moving average is 0.24% while it has a distance of 8.52% from the 200 days simple moving average. On year trading price range hit the peak level of $37.52 and touched the lowest level of $28.41 and its distance from 52 week high is -3.94% and current price is above +27.82% from 52 week low.